期刊
MOLECULAR GENETICS AND METABOLISM REPORTS
卷 27, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ymgmr.2021.100722
关键词
Congenital erythropoietic porphyria; Iron deficiency; ALAS2; Therapeutic phlebotomy; UROS; Heme synthesis
资金
- Laboratory of Excellence GREx [ANR-11-LABX-0051]
- programme Investissements d'avenir of the French National Research Agency [ANR-11-IDEX-0005-02]
- Institut National de la Sante et de la Recherche medicale (INSERM)
- University of Bordeaux
Congenital erythropoietic porphyria is a rare genetic disorder characterized by UROS deficiency, resulting in ineffective erythropoiesis and skin fragility. Therapeutic options are limited, but inducing iron depletion through phlebotomies may effectively reduce porphyrin accumulation and improve disease symptoms without causing anemia.
Congenital erythropoietic porphyria (CEP) is an autosomal recessive disorder of the heme biosynthetic pathway that is characterized by uroporphyrinogen III synthase (UROS) deficiency and the accumulation of nonphysiological isomer I porphyrins. These phototoxic metabolites predominantly produced by the erythron result in ineffective erythropoiesis, chronic hemolysis and splenomegaly, but they also disseminate in tissues causing bullous photosensitivity to UV light and skin fragility that may progress to scarring with photo mutilation. Therapeutic management is currently limited to supportive care and bone marrow transplantation is reserved for the most severe cases. We describe here a 26-year-old women previously diagnosed with CEP harbouring two novel UROS gene mutations whose pathogenic mechanism was investigated by extensive molecular analysis. Clinical features included disabling hypertrichosis and skin photosensitivity without hemolysis. The first and rate-limiting 5-aminolevulinate synthase 2 (ALAS2) enzyme controls heme synthesis and porphyrin production in erythroid cells, while iron availability modulates its expression through a post-transcriptional mechanism. We performed iterative phlebotomies over 26 months to induce iron depletion in the patient and investigated the effectiveness and tolerance of this cost-effective approach. We observed a progressive decrease in plasma ferritin and urinary porphyrins upon treatment without inducing anemia. The patient reported improved quality of life and photosensitivity. Our data confirm recent reports highlighting the benefit of iron restriction on the disease phenotype through a reduction in porphyrin accumulation. This new strategy may represent an efficient and well-tolerated treatment for CEP patients with skin involvement and limited hematological component if iron restriction is carefully monitored.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据